| $376M | ||
| $350M | ||
| $215M | ||
| $127M | ||
| $107M | ||
| $100M |
Buys | $ | – | |
Sells | $ | – |
Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, and uveal melanoma, as well as an investigator sponsored trial to treat cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.
Over the last 12 months, insiders at Turnstone Biologics Corp. have bought $undefined and sold $undefined worth of Turnstone Biologics Corp. stock.
On average, over the past 5 years, insiders at Turnstone Biologics Corp. have bought $7.7M and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 225,000 shares for transaction amount of $2.7M was made by Versant Ventures V, LLC (10 percent owner) on 2023‑07‑25.
| Increased Positions | 0 | 0% | 0 | 0% |
| Decreased Positions | 0 | 0% | 0 | 0% |
| New Positions | 0 | New | 0 | New |
| Sold Out Positions | 0 | Sold Out | 0 | Sold Out |
| Total Postitions | 0 | 0% | 0 | 0% |